Hämochromatose-assoziierte Arthropathien

Abstract

Arthropathy is the most common and often the earliest clinical manifestation of hereditary hemochromatosis (HH). It is difficult to treat and there is a high risk for early endoprosthetic joint replacement. Research done during the last decade shows that it is a joint disease in its own right. Clinically, there are degenerative articular changes with an atypical pattern of distribution, a crystal arthropathy (CPPD) with congenital joint swelling and synovitis like in RA. The X-ray image shows typical but not exclusive findings. In MRI, groundbreaking subchondral findings are found, especially in the large joints, and ultrasound shows inflammatory lesions in non-arthropathy patients as well. In animal experiments and pathomorphological studies of the synovial membrane, the arthropathy can be differentiated from osteoarthrits and RA. The pathophysiological significance of iron overload can be distinguished from immunohistochemical and cytogenetic investigations in chronic degenerative HH arthropathy and inflammatory-destructive arthropathy in hemophilia. By elucidating the pathophysiology, new therapeutic approaches can be formulated. In addition to colchicine, the IL-1 receptor antagonist anakinra is available for activation of the NLRP3 inflammasome by CPPD crystals and subsequent induction of IL-1β overproduction. Other manifestations include symptomatic pain therapy and intensive physiotherapy and occupational therapy. To promote further research into hemochromatosis arthropathy, the Hemochromatosis Arthropathy Research Initiative (HARI) was established in 2016.

Die Arthropathie bei hereditärer Hämochromatose ist die häufigste und oft auch früheste klinische Manifestation der Erkrankung. Die korrekte Diagnosestellung ist von hoher Relevanz, da eine adäquate Therapie nicht nur relevante Endorganschäden verhindert, sondern auch Lebensqualität und Lebenserwartung beeinflussen kann. Jedoch ist das für die Arthropathie selbst oft schwierig.

Schlüsselwörter

Hämochromatose - Arthropathie - Pathophysiologie - Forschungsinitiative

Key words

haemochromatosis - arthropathy - pathophysiology - research initiative

• Literatur

• 1 Oppl P, Zwerina J. Hämochromatose. Z Rheumatol 2015; 74: 609-617 . doi:10.1007/s00393-015-1583-4
• 2 Zwerina J, Dallos T. Arthrosen bei hereditären Stoffwechselerkrankungen. Orthopäde 2010; 39: 637-646 . doi:10.1007/s00132-010-1646-9
• 3 Trousseau A diabète sucré. 2nd. ed Paris: Clinique Medicale de l’Hôộtel-Dieu de Paris; 1865: 663-698
• 4 Schumacher Jr HR. Hemochromatosis and arthritis. Arthritis and Rheumatism 1964; 7: 41-50
• 5 Van Vulpen LFD, Roosendaal G, Sweder van Asbeck B. et al. The detrimental effects of iron on the joint: A comparison between haemochromatosis and haemophilia. J Clin Pathol 2015; 68: 592-600 . doi:10.1136/clinpath-2015-20296
• 6 Camacho A, Funck-Brentano T, Simao M. et al. Effect of C282Y Genotype on Self-Reported Musculoskeletal Complications in Hereditary Hemochromatosis. PLOS one 2015; 10 (03) e 0122817 . doi:10.1371/journal.pone.0122817
• 7 Sahinbegovic E, Dallos T, Aigner E. et al. Muskuloskeletal Disease Burden of Hereditary Hemochromatosis. Arthritis & Rheumatism 2010; 62 (12) 3792-3798 . doi:10.1002/art27712
• 8 Guggenbuhl P, Brissot P, Loréal O. Hemochromatosis: The bone and the joint. Best Practise & Research Clinical Rheumatology 2011; 22: 649-664 . doi:10.1016/j.berh.2011.10.014
• 9 Dallos T, Sahinbegovic E, Stamm T. et al. Idiopathic hand osteoarthritis vs haemochromatosis arthropathy – a clinical, functional and radiographic study. Rheumatology 2013; 52: 910-915 . doi:10.1093/rheumatology/kes392
• 10 Elstob A, Ejindu V, Heron CW. et al. MRI ankle and subtalar charakteristics in haemochromatosis arthropathy: a case-control study. Clin Radiology 2018; 73 (03) 323.e1-323.e8 . doi:10.1016/j.crad.2017.10.002
• 11 Dallos T, Sahinbegovic E, Aigner E. et al. Validation of a radiographic scoring system for haemochromatosis arthropathy. Ann Rheum Dis 2010; 69: 2145-2151 . doi:10.1136/ ard.2009122119
• 12 Husar-Memmer E, Stadlmayer A, Datz C. et al. HFE-related Hemochromatosis: An Update fort the Rheumatologist. Curr Rheumatol Rep 2014; 16: 393-399 . doi:10.1007/s11926-013-0393-4
• 13 Allen KJ, Bertalli NA, Osborne NJ. et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 micrg/L are at low risk of hemochromatosis. Hepatology 2010; 52: 925-933
• 14 Aigner E, Schmid I, Oesterreicher CH. et al. Contribution of anticyclic citrullinated peptide antibody and rheumatoid factor to the diagnosis of arthropathy in hemochromatosis. Ann Rheum Dis 2007; 66 (09) 1249-1251
• 15 Montgomery KD, Williams JR, Sculco TP. et al. Clinical and pathological findings in hemochromatosis hip arthropathy. Clin Orthop Relat Res 1998; 347: 179-187
• 16 Duval H, Lancien G, Marin F. Hip involvement in hereditary hemochromatosis: A clinical-pathologic study. Joint Bone Spine 2009; 76: 412-415 . doi:10.1016/j.jbspin.2008.11.012
• 17 Dejaco C, Stadlmayr A, Duftner C. et al. Ultrasound verified inflammation and structural damage in patients with hereditary hemochromatosis-related arthropathy. Arthritis Research & Therapy 2017; 19: 243-253 . doi:10.1186/s13075-017-1448-0
• 18 Camacho A, Simao M, Ea HK. Iron overload in a murine model of hereditary hemochromatosiss associated with accelerated progression of osteoarthritis under mechanical stress. Osteoarthritis and Cartilage 2016; 24: 494-502 . doi:10.1016/j.joca.2015.09.007
• 19 Ruiz Heiland G, Aigner E, Dallos T. Synovial immunopathology in haemochromatosis arthropathy. Ann Rheum Dis 2010; 69: 1214-1219 . doi:10.1136/ard.2009.120204
• 20 Sofat N, Harrison A, Russel MD. et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis. Journal of Pain Research 2017; 10: 2437-2449
• 21 Frenzen K, Schäfer C, Keyßer G. et al. Erosive and inflammatory joint changes in hereditary hemochromatosis arthropathy detected by low-field magnetic resonance imaging. Rheumatol Int 2013; 33: 2061-2067